Views & Analysis 4 principles for the future of pharma marketing COVID-19 has disrupted markets and accelerated digital adoption but what does this mean for the future of marketing?
News AstraZeneca sells rights to cholesterol drug Crestor to Grun... AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal.
Views & Analysis How COVID-19 is changing the sales model The COVID-19 pandemic means that reps can no longer speak face-to-face with physicians and many HCPs simply don’t have the time to engage with pharma.
News Mundipharma, Grünenthal accused of kickbacks in Italy Two manufacturers of opioid analgesics – Mundipharma and Grünenthal – have been accused of paying an Italian doctor to promote use of the drugs.
News Grünenthal buys certain rights to AZ’s Nexium and Vimovo for... AstraZeneca has agreed to sell some of the rights to its drugs Nexium and Vimovo to Grünenthal for an upfront payment of $922 million.
News AZ considers options as US gout drug deal backfires Ironwood tears up licensing agreement after sales disappoint
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
